Pune, June 28, 2019 (GLOBE NEWSWIRE) -- The global Parkinson’s disease drugs Market is likely to grow in the coming years due to the growing emphasis on the treatment of Parkinson's disease. According to a report published by Fortune Business Insights, titled “Parkinson’s disease drugs Market : Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 4,500.0 Mn in 2018. Fortune Business Insights states that the market will reach US$ 8,383.2 Mn by 2026, thereby exhibiting a CAGR of 8.1%.

FDA Approves Two New Drugs for Treatment of Parkinson’s Disease

Increasing usage approvals are contributing to the growth of the global Parkinson’s disease drugs Market. The Food and Drug Administration recently cleared two new drugs for the treatment of Parkinson’s disease. The drug approvals for Rytary and Duopa will emerge as breakthroughs in the healthcare industry.

Sample PDF https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/parkinson-s-disease-drugs-market-100655

FDA Clears ‘Rytary’ capsule

In 2015, Impax Pharmaceuticals announced that it has received approval from the FDA for the clinical use of Rytary. This drug was a formulation of carbidopa and levodopa and has recorded excellent clinical results for the treatment of Parkinson’s disease. The company announced that it has manufactured oral capsules with the combination of carbidopa and levodopa. The company states that the Rytary capsule can help reduce the time needed for the treatment of Parkinson’s disease. The oral form of drug delivery eliminates the need for an invasive method. This, in turn, is likely to affect the demand for Rytary capsules in a positive manner. Increasing demand for Rytary will have a positive impact on the global market and is likely to favor growth of the market in the coming years.

AbbVie gets FDA Nod for Orphan Drug ‘Duopa’

The report includes an in-depth analysis of various drug approvals and their effect on the global market. In addition to the clearance for Rytary, the FDA approved another drug in the same year which was also associated with the treatment of Parkinson’s disease. ‘AbbVie’, a pharmaceutical company, announced that it had received approval for the commercialization of its ‘Duopa’. The duopa can be used for treating fluctuations in patients diagnosed with advanced Parkinson's disease. The Duopa was classified as an orphan drug as it is used to treat a rare disease that is affecting fewer than 200,000 people in the United States.

Fortune Business Insights has predicted that the aforementioned drug approvals may have a direct impact on the vendor scale. Competitors are likely to be encouraged by the approvals for Parkinson’s disease drugs. This, in turn, is likely to favor growth of the global market in the coming years.Fortune Business Insights has profiled some of the companies that are adopting exceptional business strategies in the global Parkinson’s disease drugs Market. The report includes assesses the impact that these companies have on the global market. The report also includes the latest mergers and acquisitions and company agreements, along with their effect on the global Parkinson’s disease drugs Market.

Speak to Analyst https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/parkinson-s-disease-drugs-market-100655

Key companies covered

• Pfizer, Inc.
• Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Orion Pharma
• UCB S.A
• Teva Pharmaceutical Industries Ltd.
• Vertical Pharmaceuticals, LLC
• ACADIA Pharmaceuticals Inc.
• Impax Laboratories, Inc.
• Lundbeck A/S
• Other players

Browse Complete Report Details Enabled with Complete Tables and Figures:
https://www.fortunebusinessinsights.com/industry-reports/parkinson-s-disease-drugs-market-100655

Table of Content:

• Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Opportunities 
  • Market Trends
    
    
• Key Insights
  • Prevalence of Parkinson's Disease - For Key Countries, 2018
  • Regulatory Scenario - For Key Countries
  • Patent Snapshot
  • New Product Launch
  • Pipeline Analysis
  • Key Industry Developments -Mergers, Acquisitions and Partnerships
    
    
• 5. Global Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025 
  • Key Findings / Summary
    
    
  • Market Analysis, Insights and Forecast – By Drug Class
    • Decarboxylase Inhibitors
    • Dopamine Agonists
    • Monoamine Oxidase Type B (MAO-B) Inhibitors
    • Catechol-O-Methyltransferase (COMT) Inhibitors
    • Others
      
      
  • Market Analysis, Insights and Forecast – By Route of Administration
    • Oral
    • Injection
    • Transdermal
      
      
  • Market Analysis, Insights and Forecast – By Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Stores
      
      
  • Market Analysis, Insights and Forecast – By Region
    • North America
    • Europe
    • Asia Pacific 
    • Latin America
    • Middle East & Africa

• Competitive Analysis   
• Strategic Recommendations    

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/parkinson-s-disease-drugs-market-100655

Browse Related Reports:

• Hemophilia Drugs Market Size, Share and Global Trend by Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025
  
  
• Plant-Based Protein Supplements Market Size, Share and Global Trend by Product Type (Soy Protein, Pea Protein, Wheat Protein), Distribution Channel (Mass Merchandisers, Pharmacies/Drugstores, Specialty Stores, Online Retail), and Geography Forecast till 2025
  
  
• Veterinary Drugs Market Size, Share and Global Trend by Product (Anti-infectives, Anti-inflammatory, Parasiticides, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral,Topical), Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others,) and Geography Forecast till 2025

• Multiple Sclerosis Drugs Market Size, Share and Global Trend by Drug Class (Immunomodulatory, Immunosuppressant, Interferons, Others), By Route of Administration (Oral, Injection), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Geography Forecast till 2025

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. 

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact us:
Fortune Business Insights Pvt. Ltd. 
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1-424-253-0390
UK :+44-2071-939123
APAC :+91-744-740-1245
Email: sales@fortunebusinessinsights.com 
Website: https://www.fortunebusinessinsights.com

Attachment

• Acadia Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, and UCB S.A to Account for More Than Half of the Market Share in Terms of Revenue